A report released today by HC Wainwright about Mirna Therapeutics Inc (NASDAQ:MIRN) lowers the target price to $2.00
- Updated: September 24, 2016
In a report released on 9/23/2016 HC Wainwright reduced the stock price target of Mirna Therapeutics Inc (NASDAQ:MIRN) from $6.00 to $2.00 indicating a possible upside of 0%.
Previously on 09/22/2016, Citigroup reported on Mirna Therapeutics Inc (NASDAQ:MIRN) reduced the target price from $4.50 to $2.00. At the time, this indicated a possible downside of -0.01%.
Yesterday Mirna Therapeutics Inc (NASDAQ:MIRN) traded 3.06% higher at $2.00. The company’s 50-day moving average is $2.98 and its 200-day moving average is $4.07. The last closing price is down -50.35% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 61,560 shares of MIRN exchanged hands, up from an avg. volume of 28,677
With a total market value of $0, Mirna Therapeutics Inc has with a 52 week low of $1.82 and a 52 week high of $11.01 .
In addition to HC Wainwright reporting its target price, a total of 4 firms have reported on the stock. The consensus stock price target is $11.00 with three analysts rating the company a strong buy, one brokerage rating the company a buy, zero brokers rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
General Information About Mirna Therapeutics Inc (NASDAQ:MIRN)
Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.